Home/Pipeline/NMRA-898

NMRA-898

Schizophrenia

PreclinicalActive

Key Facts

Indication

Schizophrenia

Phase

Preclinical

Status

Active

Company

Neumora Therapeutics

About Neumora Therapeutics

Neumora Therapeutics is a clinical-stage biotech company founded in 2019 with a mission to revolutionize neuroscience drug development through data-driven precision medicine. Its core strategy involves using a proprietary platform to identify biologically defined patient populations and advance a pipeline of novel, best-in-class therapeutics for major depressive disorder, schizophrenia, Alzheimer's agitation, and Parkinson's disease. The company's lead asset, navacaprant, is a novel kappa opioid receptor antagonist in Phase 3 development for MDD, representing a significant near-term catalyst.

View full company profile

Therapeutic Areas

Neuropsychiatry Neurodegeneration

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Olanzapine LAI (TEV-‘749)	Teva	Phase 3	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active
Preclinical Kv3 Modulators	Autifony Therapeutics	Preclinical	Active